TWiV 1158: Clinical update with Dr. Daniel Griffin

This Week in Virology

In his weekly clinical update, Dr. Griffin informs us about mpox circulation and new vaccine approval, the Marburg virus outbreak in Rwanda, and the largest outbreak of whooping cough in a decade before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, immunity among those over 65th following the 3rd dose of the COVID-19 mRNA vaccine, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, how well the SARS-CoV-2 rapid antigen test performed, what do when healthcare workers succumb to SARS-CoV-2 infection, the effect of remdesivir on survival and readmission of hospitalized patients, if cognitive impairment following virus infection impairs one’s driving and how long COVID affects Chinese society.

Subscribe (free): Apple Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Undiagnosed MPXV infections are high in men who have sex with men (BMC Infectious Diseases)
• WHO, now a vaccine approval agency, Jynneos for teens (CIDRAP)
• Mpox outbreak global trends (WHO)
• How to stop Marburg virus (Rwanda Biomedical Centre)
• Marburg virus fact sheet (Rwanda Biomedical Centre)
• Largest whooping cough outbreak in US in a decade (NPR)
• COVID-19 deaths (CDC)
• COVID-19 national and regional trends (CDC)
• Waste water scan for 11 pathogens (WastewaterSCan)
• COVID-19 variant tracker (CDC)
• SARS-CoV-2 genomes galore (Nextstrain)
• Insurance relates to effectiveness and waning of immunity following 3rd dose of mRNA COVID-19 vaccine? (JID)
• New preventive COVID-19 agent (ISDA)
• IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA)
• Where to get pemgarda (Pemgarda)
• EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
• How well do you test: performance of the SARS-CoV-2 antigen rapid detection test (eBioMedicine)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Drug interaction checker (University of Liverpool)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• What to do when sick with a respiratory virus (CDC)
• When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids, dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Remdesivir-associated survival outcomes among immunocompromised patients (CID)
• Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission in Vulnerable Patients (CID)
• Measurement of circulating viral antigens post-SARS-CoV-2 infection (CMI: Clinical Microbiology and Infection)
• DUCI: driving under cognitive influence of COVID-19 (Neurology)
• Long COVID facts and findings: (LANCET: Regional Health Western Pacific)
• Letters read on TWiV 1158
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [e-mail]